Danaher Corp
DHRQ2 2024(DHR Q1 FY2024)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$726.6M
AI Revenue (Q)
$58.0M
Total Revenue (Q)
$5.8B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q1 FY2024 (three-month period ended March 29, 2024). Total sales $5,796M (continuing operations, 3 segments). Segments: Biotechnology $1,524M, Life Sciences $1,745M, Diagnostics $2,527M. No AI revenue disclosure. No mention of AI in filing beyond risk factor boilerplate. DHR remains a hardware/consumables business. Conservative 1% estimate for embedded algorithmic content in instruments. Math: ~$58M estimated / $5,796M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $5,796 [three-month period ended March 29, 2024]
10-Q Q1 FY2024, Consolidated Condensed Statements of Earnings
Biotechnology $1,524; Life Sciences $1,745; Diagnostics $2,527 [three-month period ended March 29, 2024]
10-Q Q1 FY2024, Note 6 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instruments
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix